Evidence map›Paper›PMID 41613793›Full record

ArticleOncology research2026

The FN1-ITGB4 Axis Drives Acquired Chemoresistance in Bladder Cancer by Activating FAK Signaling.

Xiaoyu Zhang, RenFei Zong, Yan Sun, Nan Chen, Kunyao Zhu, Hang Tong, Tinghao Li, Junlong Zhu, Zijia Qin, Linfeng Wu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaoyu ZhangDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
RenFei ZongDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Yan SunDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Nan ChenDepartment of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Kunyao ZhuDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Hang TongDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Tinghao LiDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Junlong ZhuDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zijia QinDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Linfeng WuDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Aimin WangDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Weiyang HeDepartment of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: While cisplatin-based chemotherapy is pivotal for advanced bladder cancer, acquired resistance remains a major obstacle. This study investigates key molecular drivers of this resistance and potential reversal strategies. Methods: We established GC (Gemcitabine and Cisplatin)-resistant T24-R and UC3-R cell lines from T24 and UM-UC-3 (UC3) cells. Transcriptomic and proteomic analyses identified differentially expressed molecules. Apoptosis and cell viability were assessed by flow cytometry and CCK-8 (Cell Counting Kit-8) assays, while RT-qPCR (Reverse Transcription Quantitative Polymerase Chain Reaction) and Western blot analyzed gene and protein expression. Immunofluorescence evaluated FAK (Focal Adhesion Kinase) phosphorylation, and a xenograft mouse model validated the findings Results: Integrated transcriptomic and proteomic analysis identified FN1 (fibronectin) as a consistently upregulated top candidate in resistant cells (T24-R transcript log Conclusion: Our results demonstrate that the FN1-ITGB4 axis drives chemoresistance in bladder cancer via FAK signaling. Targeting this axis represents a promising strategy to overcome chemoresistance.

Indexed as

Drug Resistance, NeoplasmFibronectinsFocal Adhesion Kinase 1Integrin beta4Urinary Bladder NeoplasmsAnimalsApoptosisCell Line, TumorCisplatinDeoxycytidineFocal Adhesion Protein-Tyrosine KinasesGemcitabineGene Expression Regulation, NeoplasticHumansMiceSignal TransductionCisplatinDeoxycytidineFibronectinsFN1 protein, humanFocal Adhesion Kinase 1Focal Adhesion Protein-Tyrosine KinasesGemcitabineIntegrin beta4PTK2 protein, humanBladder cancerchemoresistancefibronectinfocal adhesion kinasegemcitabine and cisplatinintegrin subunit beta 4

Identifiers

PMID41613793
PMCPMC12848685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.